Anna Yordanova1, Karin Mayer2, Peter Brossart2, Maria A Gonzalez-Carmona3, Christian P Strassburg3, Markus Essler1, Hojjat Ahmadzadehfar4. 1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. 2. Department of Internal Medicine 3, University Hospital Bonn, Bonn, Germany. 3. Department of Internal Medicine 1, University Hospital Bonn, Bonn, Germany. 4. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. hojjat.ahmadzadehfar@ukbonn.de.
Abstract
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how many cycles of 177Lu-octreotate can be repeated while maintaining an acceptable toxicity profile. The purpose of this study was to assess the safety of repeated PRRT in patients with recurrent NET. METHODS: We retrospectively evaluated data from 15 patients treated with repeated PRRT between 2004 and 2015. The median administered activity was 63.8 GBq (range 52-96.6 GBq) in a median of 9 cycles (range 8-13 cycles). Nonhaematological and haematological toxicities were assessed from clinical reports and laboratory data. The rates of adverse events in three therapy groups were compared: during cycles 1 to 4, cycles 5 to 8, and cycles 9 to 13. Baseline laboratory assessments were also compared with data obtained at the end of treatment. The overall survival in the study patients was compared with survival data in patients who received only a baseline PRRT of three or four cycles. RESULTS: We observed no life-threatening adverse events (CTC-4) during 177Lu-octreotate treatment. Reversible haematological toxicity (CTC-3) occurred in two patients (13%). No CTC-3/4 nephrotoxicity was recorded. More CTC-3 adverse events were recorded in the first therapy group than in the other two groups. Furthermore, there were no significant changes in the mean values of thrombocytes, leucocytes and serum creatinine before and after therapy. However, the mean haemoglobin levels fell from 14 g/dL to 11 g/dL. Finally, compared with those patients who received three or four cycles, there was a survival benefit in patients treated with repeated PRRT (censored overall survival 85.6 vs. 69.7 months, p < 0.001). CONCLUSION: Therapy with eight or more cycles of 177Lu-octreotate was well tolerated and led to a survival benefit in patients with recurrent NET.
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how many cycles of 177Lu-octreotate can be repeated while maintaining an acceptable toxicity profile. The purpose of this study was to assess the safety of repeated PRRT in patients with recurrent NET. METHODS: We retrospectively evaluated data from 15 patients treated with repeated PRRT between 2004 and 2015. The median administered activity was 63.8 GBq (range 52-96.6 GBq) in a median of 9 cycles (range 8-13 cycles). Nonhaematological and haematological toxicities were assessed from clinical reports and laboratory data. The rates of adverse events in three therapy groups were compared: during cycles 1 to 4, cycles 5 to 8, and cycles 9 to 13. Baseline laboratory assessments were also compared with data obtained at the end of treatment. The overall survival in the study patients was compared with survival data in patients who received only a baseline PRRT of three or four cycles. RESULTS: We observed no life-threatening adverse events (CTC-4) during 177Lu-octreotate treatment. Reversible haematological toxicity (CTC-3) occurred in two patients (13%). No CTC-3/4 nephrotoxicity was recorded. More CTC-3 adverse events were recorded in the first therapy group than in the other two groups. Furthermore, there were no significant changes in the mean values of thrombocytes, leucocytes and serum creatinine before and after therapy. However, the mean haemoglobin levels fell from 14 g/dL to 11 g/dL. Finally, compared with those patients who received three or four cycles, there was a survival benefit in patients treated with repeated PRRT (censored overall survival 85.6 vs. 69.7 months, p < 0.001). CONCLUSION: Therapy with eight or more cycles of 177Lu-octreotate was well tolerated and led to a survival benefit in patients with recurrent NET.
Authors: Dik J Kwekkeboom; Wouter W de Herder; Casper H J van Eijck; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Eric P Krenning Journal: Semin Nucl Med Date: 2010-03 Impact factor: 4.446
Authors: D J Kwekkeboom; W H Bakker; P P Kooij; M W Konijnenberg; A Srinivasan; J L Erion; M A Schmidt; J L Bugaj; M de Jong; E P Krenning Journal: Eur J Nucl Med Date: 2001-09
Authors: Roelf Valkema; Marion De Jong; Willem H Bakker; Wout A p Breeman; Peter P m Kooij; Pieternella J Lugtenburg; Frank H De Jong; Arjan Christiansen; Boen L r Kam; Wouter W De Herder; Mats Stridsberg; Jan Lindemans; Geert Ensing; Eric P Krenning Journal: Semin Nucl Med Date: 2002-04 Impact factor: 4.446
Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: B L R Kam; J J M Teunissen; E P Krenning; W W de Herder; S Khan; E I van Vliet; D J Kwekkeboom Journal: Eur J Nucl Med Mol Imaging Date: 2012-02 Impact factor: 9.236
Authors: Bryson W Katona; Giorgio A Roccaro; Michael C Soulen; Yu-Xiao Yang; Bonita J Bennett; Brian P Riff; Rebecca A Glynn; Damian Wild; Guillaume P Nicolas; Daniel A Pryma; Ursina R Teitelbaum; David C Metz Journal: Pancreas Date: 2017-10 Impact factor: 3.327
Authors: Zahraa Abdul Sater; Abhishek Jha; Ahmed Hamimi; Adel Mandl; Iris R Hartley; Sriram Gubbi; Mayank Patel; Melissa Gonzales; David Taïeb; Ali Cahid Civelek; Ahmed M Gharib; Sungyoung Auh; Alana E O'Mara; Karel Pacak; Aaron M Cypess Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Katherine I Wolf; Abhishek Jha; Anouk van Berkel; Damian Wild; Ingo Janssen; Corina M Millo; M J R Janssen; Melissa K Gonzales; Henri J K M Timmers; Karel Pacak Journal: Nucl Med Mol Imaging Date: 2019-02-22
Authors: Anna Yordanova; Elisabeth Eppard; Stefan Kürpig; Ralph A Bundschuh; Stefan Schönberger; Maria Gonzalez-Carmona; Georg Feldmann; Hojjat Ahmadzadehfar; Markus Essler Journal: Onco Targets Ther Date: 2017-10-03 Impact factor: 4.147